Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:32 PM
Ignite Modification Date:
2025-12-24 @ 5:32 PM
NCT ID:
NCT01661868
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has recurred following a platinum-based regimen used at initial diagnosis
* Measurable disease
* Estimated life expectancy greater than 16 weeks
* Normal organ and marrow function
* Evidence of non-childbearing status for women of childbearing potential
* Able to swallow oral medication
Exclusion Criteria:
* Pregnant or breastfeeding
* Prior PARP inhibitor use for another cancer such as breast cancer
* Receiving any other study agents or any other anti-cancer treatment
* Known brain metastases
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* History of a different malignancy unless disease-free for at least 5 years
* Currently experiencing seizures or currently being treated with any anti-epileptic for seizures
* Human immunodeficiency virus (HIV) positive on combination antiretroviral therapy
* Presence of gastrointestinal disorders that, in the investigator's opinion, are likely to interfere with the absorption of olaparib, or with the patient's ability to take regular oral medication
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT01661868
Study Brief:
Protocol Section:
NCT01661868